SeaCrest Wealth Management’s Sarepta Therapeutics SRPT Stock Holding History

SeaCrest Wealth Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-2,936	Closed	-$221K	–	582
2019 Q3	$221K	Buy	2,936 +85	+3%	+$10K	0.04%	468
2019 Q2	$433K	Sell	2,851 -56	-2%	-$6.81K	0.09%	274
2019 Q1	$346K	Buy	2,907 +55	+2%	+$7.07K	0.06%	326
2018 Q4	$311K	Buy	2,852 +607	+27%	+$75.9K	0.06%	319
2018 Q3	$363K	Sell	2,245 -81	-3%	-$11.1K	0.06%	342
2018 Q2	$307K	Buy	2,326 +863	+59%	+$81.4K	0.06%	371
2018 Q1	$108K	Sell	1,463 -2,870	-66%	-$191K	0.02%	681
2017 Q4	$241K	Buy	+4,333	New	+$230K	0.04%	435

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

SeaCrest Wealth Management's SRPT Position: Q4 2019 in Review

SeaCrest Wealth Management sold out of Sarepta Therapeutics (SRPT) in Q4 2019, closing a stake of 2,936 shares — an estimated $221K sold.

SeaCrest Wealth Management first reported a position in SRPT in Q4 2017 and held it in 8 quarters. The position peaked at $433K in Q2 2019. 389 funds tracked by Wall St. Rank hold SRPT as of Q4 2019.

SeaCrest Wealth Management reported no remaining Sarepta Therapeutics position as of Q4 2019 after selling out during the quarter.
SeaCrest Wealth Management sold 2,936 Sarepta Therapeutics shares in Q4 2019, an estimated $221K.
SeaCrest Wealth Management first reported a position in Sarepta Therapeutics in Q4 2017 and held it in 8 quarters.
SeaCrest Wealth Management's Sarepta Therapeutics position peaked at $433K in Q2 2019.
389 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2019.

Based on SeaCrest Wealth Management's 13F filing for Q4 2019, filed 22 Jan 2020.